YM155 is an imidazolium-based inhibitor of survivin in a dose-dependent manner when administered from 10 to 1000 nM. YM155 suppresses survivin expression and induces apoptosis in PC-3 and PPC-1 human hormone-refractory prostate cancer (HRPC) cell lines at 10 nM. In addition to other HRPC cell lines, YM155 also shows activity against malignant melanoma lines SKMEL5 and A375 at GI50s of 4.2 and 6.3 nM, respectively. [1]

In independent studies, YM155 was shown to inhibit SK-NEP-1 Wilms tumor cells at an IC50 of 100 nM, while concurrently inducing apoptosis. [2]

YM155 is believed to sensitize NSCLC cells to radiation both in vivo and in vitro by downregulating survivin expression in a concentration- and time-dependent manner. YM155 delays the repair of radaiation-induced double-strand breaks in nuclear DNA. [3]

YM155 is an imidazolium-based inhibitor of survivin in a dose-dependent manner when administered from 10 to 1000 nM. YM155 suppresses survivin expression and induces apoptosis in PC-3 and PPC-1 human hormone-refractory prostate cancer (HRPC) cell lines at 10 nM. In addition to other HRPC cell lines, YM155 also shows activity against malignant melanoma lines SKMEL5 and A375 at GI50s of 4.2 and 6.3 nM, respectively. [1]

In independent studies, YM155 was shown to inhibit SK-NEP-1 Wilms tumor cells at an IC50 of 100 nM, while concurrently inducing apoptosis. [2]

YM155 is believed to sensitize NSCLC cells to radiation both in vivo and in vitro by downregulating survivin expression in a concentration- and time-dependent manner. YM155 delays the repair of radaiation-induced double-strand breaks in nuclear DNA. [3]